罗伐他汀对中度心血管风险男性艾滋病患者脉搏波速度的影响。

IF 3.4 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2024-09-01 Epub Date: 2024-08-01 DOI:10.1097/QAD.0000000000003930

Janine M Trevillyan, Anthony Dart, Eldho Paul, Elizabeth M Dewar, Victoria G Hall, Jennifer F Hoy

{"title":"罗伐他汀对中度心血管风险男性艾滋病患者脉搏波速度的影响。","authors":"Janine M Trevillyan, Anthony Dart, Eldho Paul, Elizabeth M Dewar, Victoria G Hall, Jennifer F Hoy","doi":"10.1097/QAD.0000000000003930","DOIUrl":null,"url":null,"abstract":"This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96 weeks of rosuvastatin on pulse wave velocity (PWV) in men (n = 55, 54 years) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54 m/s standard error of difference (SED) 0.26] and placebo [0.50 m/s (SED 0.26), P = 0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40 m/s (SE 0.31); placebo 9.21 m/s (SE0.31), P = 0.676].","PeriodicalId":7502,"journal":{"name":"AIDS","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk.\",\"authors\":\"Janine M Trevillyan, Anthony Dart, Eldho Paul, Elizabeth M Dewar, Victoria G Hall, Jennifer F Hoy\",\"doi\":\"10.1097/QAD.0000000000003930\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96 weeks of rosuvastatin on pulse wave velocity (PWV) in men (n = 55, 54 years) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54 m/s standard error of difference (SED) 0.26] and placebo [0.50 m/s (SED 0.26), P = 0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40 m/s (SE 0.31); placebo 9.21 m/s (SE0.31), P = 0.676].\",\"PeriodicalId\":7502,\"journal\":{\"name\":\"AIDS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAD.0000000000003930\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000003930","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

这项双盲、随机、安慰剂对照试验的单中心子研究旨在确定服用罗伐他汀 96 周对中度心血管风险（弗雷明汉风险评分 10-15%）男性艾滋病患者（n = 55，54 岁）脉搏波速度（PWV）的影响。罗伐他汀治疗组[0.54 m/s 标准差（SED）0.26]和安慰剂治疗组[0.50 m/s (SED 0.26)，P = 0.896]的脉搏波速度均有所增加，导致第 96 周时脉搏波速度无差异[罗伐他汀 9.40 m/s (SE 0.31)；安慰剂 9.21 m/s (SE0.31), P = 0.676]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk.

This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96 weeks of rosuvastatin on pulse wave velocity (PWV) in men (n = 55, 54 years) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54 m/s standard error of difference (SED) 0.26] and placebo [0.50 m/s (SED 0.26), P = 0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40 m/s (SE 0.31); placebo 9.21 m/s (SE0.31), P = 0.676].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.